EPRSQ — Epirus Biopharmaceuticals Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro Cap

Annual cashflow statement for Epirus Biopharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2011 December 31st	2012 December 31st	R2013 December 31st	2014 December 31st	2015 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-42	-44.3	-20.8	-41.8	-52.2
Depreciation
Deferred Taxes
Non-Cash Items	1.92	1.66	5.84	4.54	3.94
Discontinued Operations
Unusual Items
Other Non-Cash Items
Changes in Working Capital	-0.454	-1.19	2.06	1.85	1.68
Change in Accounts Receivable
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Cash from Operating Activities	-33.4	-38.5	-12.9	-35.5	-46.6
Capital Expenditures	-0.35	-0.048	-0.086	-1.47	-0.477
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-3.27	15.4	0	13.8	1.32
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-3.62	15.3	-0.086	12.3	0.841
Financing Cash Flow Items	0	0	—	-0.049	0
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	36.9	24.9	12.5	42.8	55.8
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-0.07	1.78	-0.436	19.7	10.1